Substituted pyrrolo[2,3-d]pyrimidines as antifolates

Details Substituted pyrrolo[2,3-d]pyrimidines as antifolates Substituted pyrrolo[2,3-d]pyrimidines as antifolates

2011-05-31

2011-05-31

Moore, Susanna (Department: 1624)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C544S278000

Reexamination Certificate

active

07951812

ABSTRACT:
The present invention is directed to antifolate compounds having the structurewherein:X is CHR9or NR9;Y1, Y2, and Y3independently are O or S;V1and V2independently are O, S, or NZ;Z is H, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, or alkaryl;R1and R2independently are H, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, or alkaryl;R3is H, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted alkoxy, hydroxyl, or halo; andR4, R5, R6, R7, R8, and R9independently are H, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, acyl, —C(O)-alkyl, —C(O)-alkenyl, or —C(O)—alkynyl; as well as pharmaceutically acceptable esters, amides, salts, solvates, and prodrugs thereof. The compounds are useful in pharmaceutical compositions and in methods of treating multiple conditions, including abnormal cell proliferation, inflammatory diseases, asthma, and arthritis.

REFERENCES:
patent: 4818753 (1989-04-01), Colwell et al.
patent: 4996206 (1991-02-01), Taylor et al.
patent: 4996207 (1991-02-01), Nair et al.
patent: 5028608 (1991-07-01), Taylor et al.
patent: 5073554 (1991-12-01), Nair
patent: 5106974 (1992-04-01), Akimoto et al.
patent: 5248775 (1993-09-01), Taylor et al.
patent: 5344932 (1994-09-01), Taylor
patent: 5550128 (1996-08-01), Nair et al.
patent: 5593999 (1997-01-01), Nair et al.
patent: 5912251 (1999-06-01), Nair
patent: 6667318 (2003-12-01), Burdick et al.
patent: 7060825 (2006-06-01), Wu et al.
patent: 2002/0081455 (2002-06-01), Lee
patent: 2003/0181635 (2003-09-01), Kochat et al.
patent: 2006/0111272 (2006-05-01), Roberts et al.
patent: 2006/0160751 (2006-07-01), McGuire
patent: 0 239 362 (1987-09-01), None
patent: 0 340 905 (1989-11-01), None
patent: WO 93/13079 (1993-07-01), None
patent: WO 02/081455 (2002-10-01), None
Gangjee et al., “Effect of N-9-Methylation and Bridge Atom Variation on the Activity of 5-Substituted 2, 4-Diaminopyrrolo (2,3-d) Pyrimidines Against Dihydrofolate Reductases FromPneumocystis cariniiandToxoplasma gondii,” Journal of Medicinal Chemistry, 1997, pp. 1173-1177, vol. 40, No. 7.
Itoh et al., “Non-Glutamate Type Pyrrolo[2,2-d]pyrimidine Antifolates. II. Synthesis and Antitumor Activity ofN-Substituted Glutamine Analogs,”Chemical and Pharmaceutical Bulletin, Pharmaceutical Society of Japan, 1996, pp. 1498-1509, vol. 44, No. 8.
Miwa et al., “A Novel Synthetic Approach to Pyrrolo(2,3-d)pyrimidine Antifolates,”Journal of Organic Chemistry, 1993, pp. 1696-1701, vol. 58, No. 7.
McGuire, et al., “Metabolism-blocked Antifolates as Potential Anti-rheumatoid Arthritis Agents: 4-Amino-4-deoxy-5,8,10-trideazapteroyl -D,L-4′-methyleneglutamic Acid (CH-1504) and Its Analogs,”Biochemical Pharmacology, 2009, pp. 1161-1172, vol. 77, No. 7.
Abraham et al., “Folate Analogues. 34. Synthesis and Antitumor Activity of Non-Polyglutamylatable Inhibitors of Dihydrofolate Reductase,”J. Med. Chem., 1991, vol. 34, pp. 222-227.
Abraham et al., “Aldehyde Oxidase Mediated 7-Hydroxylation of Antifolates and Its Therapeutic Relevance,”Cellular Pharmacology, 1996, vol. 3, pp. 29-34.
Alarcon et al., “Controlled Trial of Methotrexate Versus 10-Deazaaminopterin in the Treatment of Rheumatoid Arthristis,”Arthritis Rheumatism, 1992, pp. 600-660, vol. 51, No. 5.
Amato et al., “Metabolism-Based Antifolate Drug Design: MDAM and MTREX,”Pharmacology and Therapeutics in the New Millennium, 2001, pp. 204-212, Narosa Publishing House, New Delhi, India.
Baggott et al., “Folylpoly-γ-glutamates as Cosubstrates of 10-Formyltetrahdrofolate:5′- Phosphoribosy1-5amino-4-imidazole-Carboxamide Formyltransferase,”Biochemistry, 1979, pp. 1036-1041, vol. 18, No. 1.
Baugh et al., “Polygammaglutamyl Metabolites of Methotrexate,”Biochemical and Biophysical Research Communications, 1973, pp. 27-34, vol. 52, No. 1.
Blakley,The Biochemistry of Folic Acid and Related Pteridines. 1969, Amsterdam Elsevier.
Broxterman et al., “Cancer Research 2001: Drug Resistance, New Targets and Drug Combinations,”Drug Resistance Updates, 2001, vol. 4, pp. 197-209.
Bryant et al., “Metabolism-Blocked Antifolate-2,”Proc. Am. Assoc. Cancer Res., 1999, vol. 40, p. 293 (Abstract No. 1944).
Caperelli et al., “The Human Glycinamide Ribonucleotide Transformylase Domain: Purification, Characterization and Kinetic Mechanism,”Archives of Biochemistry and Biophysics, 1997, pp. 98-103, vol. 341, No. 1.
Castaneda et al., “Controlled Trial of Methotrexate Versus CH-1504 in the Treatment of Rheumatoid Arthritis,”Journal of Rheumatology, 2006, pp. 862-864, vol. 33, No. 1.
Clowes et al., “Prevention of Stenosis After Vascular Reconstruction: Pharmacologic Control of Intimal Hyperplasia—A Review,”Journal of Vascular Surgery, 1991, pp. 885-890, vol. 13.
Degraw et al., “Synthesis and Antifolate Activity of 8,10-Dideazaminopterin,”J. Het. Chem., 1982, vol. 19, pp. 1587-1588.
Dolnick et al., “Human Thymidylate Synthetase Derived From Blast Cells of Patients With Acute Myelocytic Leukemia,”The Journal of Biological Chemistry, 1977, pp. 7697-7703, vol. 252, No. 1.
Gahtan et al., “Inflammatory Pathogenesis in Alzheimer's Disease: Biological Mechanisms and Cognitive Sequeli,”Neuroscience and Biobehavioral Reviews, 1999, pp. 615-633, vol. 23, No. 5.
Gangjee et al., “Nonclassical 2,4-Diamino-8-Deazafolate Analogues as Inhibitors of Dihydrofolate Reductases from Rat Liver,Pneumocystis carinii, andToxoplasma gondii,” J. Med. Chem., 1996, vol. 39(9), pp. 1836-1845.
Gangjee et al., “Design, Synthesis, and Biological Activities of ClassicalN- {4-[2-(2-Amino-4-ethylpyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl}-L-glutamic Acid and Its 6-Methyl Derivative as Potential Dual Inhibitors of Thymidylate Synthase and Dihydrofolate Reductase and as Potential Antitumor Agents,”J. Med. Chem., 2003, pp. 591-600, vol. 46, No. 4.
Gupta et al., “Inflammation and Alzheimer's Disease,”The International Journal of Clinical Practice, 2003, pp. 36-39, vol. 57, No. 1.
Jackman, “Antifolate Drugs in Cancer Therapy,” Book Review:Reprints from Current Trends, Drug Discover Today, 1999.
Johns et al., “Enzymic Oxidation of Methotrexiate and Aminopterin,”Life Sciences, 1964, pp. 1383-1388, vol. 3.
Johns et al.,“Metabolism of Folate Antagonists,”Annals New York Academy of Sciences, 1971, pp. 378-386, vol. 186.
Kisliuk, “Deaza Analogs of Folic Acid as Antitumor Agents,”Current Pharmaceutical Design, 2003, vol. 9(31), pp. 2615-2625.
Kormeili et al., Psoriasis: Immunopathogenesis and Evolving Immunomodulators and Systemic Therapies; U.S. Experiences,British Journal of Dermatology, 2004, pp. 3-15, vol. 151, No. 1.
Lemanke, “Inflammation in Childhood Asthma and Other Wheezing Disorders,”Pediatrics, 2002, pp. 368-372, vol. 109, No. 2.
Lim, et al., “Gene-Nutrient Interactions Among Determinants of Folate and One-Carbon Metabolism on the Risk of Non-Hodgkin Lymphoma: NCI-SEER Case-Control Study,”Blood, 2007, pp. 3050-3059, vol. 109, No. 7.
Lind, “Circulating Markers of Inflammation and Atherosclerosis,” Atherosclerosis, 2003, pp. 203-214, vol. 169, No. 2.
Lloyd et al., “Crystallization and Preliminary Crystallographic Analysis of Carboxypeptidase G2FromPseudomonassp. Strain RS-16,”J. Mol. Biol., 1991, pp. 17-18, vol. 220.
Matherly et al., “Membrane Transport of Folates,”Vitam Horm, 2003, pp. 403-456, vol. 66.
McCullough et al., “Purification and Properties of Carboxypeptidase G”The Journal of Biological Chemistry, 1971, pp. 7201-7213, vol. 246, No. 23.
McGuire et al., “Enzymatic Synthesis of Polyglutamate Derivatives of 7-Hydroxym

Affiliated with

Also associated with

Rating

Substituted pyrrolo[2,3-d]pyrimidines as antifolates does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Substituted pyrrolo[2,3-d]pyrimidines as antifolates, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Substituted pyrrolo[2,3-d]pyrimidines as antifolates will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2681632